医学と薬学　81/2　2024年2月号

出版社： 自然科学社
発行日： 2024-01-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 片頭痛治療―新時代の幕開け
電子書籍版： 2024-01-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,760 円(税込)

購入する

目次

  • 特集　片頭痛治療―新時代の幕開け

    序文
    片頭痛の概要―診断・疫学・誘因・共存症
    片頭痛の急性期治療―トリプタンとラスミジタン
    片頭痛の予防療法―既存治療とCGRP関連抗体薬のエビデンス
    CGRP関連抗体薬のリアルワールドデータ
    CGRP拮抗薬の開発状況と期待
    片頭痛治療におけるNeuromodulationの役割と現状

    研究
    　チオアセトアミドおよび肝臓X受容体アゴニストの投与による非アルコール性脂肪性肝炎モデルの確立

    Diagnosis
    　タクロリムス測定試薬「ルミパルスプレスト® iTACT® タクロリムス」の基礎的検討
    　検体抽出液を共通化したアデノウイルス迅速診断薬「イムノキャッチ®−Adeno」
    　　A群β溶血連鎖球菌抗原迅速診断薬「イムノキャッチ®−Strep A」の性能評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 片頭痛治療 - 新時代の幕開け】

P.119 掲載の参考文献
1) Do TP, Remmers A, Schytz HW, et al:Red and orange flags for secondary headaches in clinical practice:SNNOOP10 list. Neurology 92:134-144, 2019.
PubMed
2) 日本神経学会・日本頭痛学会・日本神経治療学会(監), 「頭痛の診療ガイドライン」作成委員会(編):頭痛の診療ガイドライン2021. 医学書院, 東京, 2021.
 
3) 国際頭痛学会・頭痛分類委員会(著), 日本頭痛学会・国際頭痛分類委員会(訳):国際頭痛分類第3版, 医学書院, 東京, 2018.
 
4) Blau JN, MacGregor EA:Migraine, and the neck. Headache 34:88-90, 1994.
PubMed
5) Sakai F, Igarashi H:Prevalence of migraine in Japan:a national wide survey. Cephalalgia 17:15-22, 1997.
 
6) Hirata K, Ueda K, Komori M, et al:Compre-hensive population-based survey of migraine in Japan:results of the ObserVational Survey of the Epidemiology, tReatment, and Care Of MigrainE(OVERCOME[Japan])study. Curr Med Res Opin 37:1945-1955, 2021.
 
7) Katsuki M, Matsumori Y, Kawahara J, et al:School-based online survey on chronic head-ache, migraine, and medication-overuse headache prevalence among children and adolescents in Japanese one city-Itoigawa Benizuwaigani study. Clin Neurol Neurosurg 226:107610, 2023.
PubMed
8) Kelman L:The triggers or precipitants of the acute migraine attack. Cephalalgia 27:394-402, 2007.
 
9) Amin FM, Aristeidou S, Baraldi C, et al:The association between migraine and physical exer-cise. J Headache Pain 19:83, 2018.
 
10) Buse DC, Reed ML, Fanning KM, et al:Comorbid and co-occurring conditions in migraine and asso-ciated risk of increasing headache pain intensity and headache frequency:results of the migraine in America symptoms and treatment(MAST) study. J Headache Pain 21:23, 2020.
 
11) 立花久大:片頭痛の共存症. 臨床神経学 62:105-11, 2022.
 
12) Tietjen EG:Migraine and Ischaemic Heart Disease and Stroke:Potential Mechanisms and Treatment Implications. Cephalalgia 27:981-987, 2007.
PubMed
13) Valecha J, Khandait H, Sk A, et al:Migraine and heart:A reality check. Glob Cardiol Sci Pract 2023:e202320, 2023.
 
P.125 掲載の参考文献
1) Goadsby PJ, Lipton RB, Ferrari MD:Migraine-current understanding and treatment. N Engl J Med 346:257-270, 2002.
PubMed
2) 日本神経学会, 日本頭痛学会, 日本神経治療学会(監), 「頭痛の診療ガイドライン」作成委員会(編):頭痛の診療ガイドライン2021, 医学書院, 東京, 2021.
 
3) Nelson DL, Phebus LA, Johnson KW, et al:Pre-clinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159-1169, 2010.
 
4) Oswald JC, Schuster NM:Lasmiditan for the treatment of acute migraine:a review and poten-tial role in clinical practice. J Pain Res 11:2221-2227, 2018.
 
5) Kuca B, Silberstein SD, Wietecha L, et al:Lasmiditan is an effective acute treatment for migraine:a phase 3 randomized study. Neurology 91:e2222-e2232, 2018.
 
6) Goadsby PJ, Dennehy EB, Kuca B, et al:Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142:1894-1904, 2019.
PubMed
7) Shapiro RE, Hochstetler HM, Dennehy EB, et al:Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors:Post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 Trials. J Headache Pain 20:90, 2019.
PubMed
8) Brandes JL, Klise S, Krege JH et al:Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine(The GLADIATOR Study). Cephalalgia 39:1343-1357, 2019.
 
9) Ashina M, Reuter U, Smith T, et al:Randomized, controlled trial of lasmiditan over four migraine attacks:Findings from the CENTURION study. Cephalalgia 41:294-304, 2021.
PubMed
10) Sakai F, Takeshima T, Homma G, et al:Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61:755-765, 2021.
PubMed
11) 伊藤康男, 荒木信夫:同種薬の特徴と使い分け-頭痛治療・予防薬-. 福井次矢, 高木誠, 小室一成(総編集):今日の治療指針2023年版私はこう治療している, pp. 899-901, 医学書院, 2023.
 
12) Lo Castro F, Guerzoni S, Pellesi L:Safety and Risk of Medication Overuse Headache in Lasmid-itan and Second-Generation Gepants:A Rapid Review. Drug Healthc Patient Saf 13:233-240, 2021.
 
13) Rau JC, Navratilova E, Oyarzo J, et al:Evaluation of LY573144(lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 40:903-912, 2020.
 
14) Zhang LQ, Zhou YQ, Li JY, et al:5-HT1F Recep-tor Agonist Ameliorates Mechanical Allodynia in Neuropathic Pain via Induction of Mitochondrial Biogenesis and Suppression of Neuroinflammation. Front Pharmacol 13:834570, 2022.
 
P.138 掲載の参考文献
1) Dahlof CG, Dimenas E:Migraine patients expe-rience poorer subjective well-being/quality of life even between attacks. Cephalalgia 15:31-36, 1995.
 
2) Takeshima T, Ishizaki K, Fukuhara Y, et al:Pop-ulation-based door-to-door survey of migraine in Japan:the Daisen study. Headache 44:8-19, 2004.
 
3) Collins JJ, Baase CM, Sharda CE, et al:The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med 47:547-557, 2005.
PubMed
4) Shimizu T, Sakai F, Miyake H, et al:Disabil-ity, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain 22:29, 2021.
 
5) 中村治雅, 鈴木啓介, 和田健二, 他:神経疾患に関する医療ニーズ調査(第2回). 神経治療学 37:187-212, 2020.
 
6) GBD 2019 Diseases and Injuries Collaborators:Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019:a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396:1204-1222, 2020.
PubMed
7) Hirata K, Ueda K, Komori M, et al:Compre-hensive population-based survey of migraine in Japan:results of the Obser Vational Survey of the Epidemiology, tReatment, and Care Of MigrainE(OVERCOME[Japan]) study. Curr Med Res Opin 37:1945-1955, 2021.
 
8) Schoonman GG, Evers DJ, Terwindt GM, et al:The prevalence of premonitory symptoms in migraine:a questionnaire study in 461 patients. Cephalalgia 26:1209-1213, 2006.
 
9) Schulte LH, May A:The migraine generator revisited:continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139:1987-1993, 2016.
PubMed
10) 国際頭痛学会・頭痛分類委員会(著), 日本頭痛学会・国際頭痛分類委員会(訳):国際頭痛分類第3版, 医学書院, 東京, 2018.
 
11) Hadjikhani N, Sanchez Del Rio M, Wu O, et al:Mechanisms of migraine aura revealed by func-tional MRI in human visual cortex. Proc Natl Acad Sci USA 98:4687-4692, 2001.
 
12) Moskowitz MA:Neurogenic inflammation in the pathophysiology and treatment of migraine. Neu-rology 43(6 Suppl 3):S16-20, 1993.
 
13) Burstein R, Jakubowski M, Garcia-Nicas E, et al:Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68:81-91, 2010.
PubMed
14) Suzuki K, Suzuki S, Haruyama Y, et al:Central sensitization in migraine is related to restless legs syndrome. J Neurol 268:1395-1401, 2021.
PubMed
15) Knight YE, Goadsby PJ:The periaqueductal grey matter modulates trigeminovascular input:a role in migraine? Neuroscience 106:793-800, 2001.
PubMed
16) Knight YE, Bartsch T, Kaube H, et al:P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception:a functional genetic link for migraine? J Neurosci 22:RC213, 2002.
 
17) Bigal ME, Lipton RB:Clinical course in migraine:conceptualizing migraine transformation. Neurol-ogy 71:848-855, 2008.
 
18) Takeshima T, Sakuma K, Imamura K, et al:Chronic daily headache and medication overuse headache:Japanese case series in the headache clinic of Tottori University Hospital. Cephalalgia 29:36-37, 2009.
 
19) 古和久典:本邦における片頭痛慢性化の実態. 臨床神経 53:1223-1224, 2013.
 
20) 日本神経学会・日本頭痛学会・日本神経治療学会(監), 「頭痛の診療ガイドライン」作成委員会(編):頭痛の診療ガイドライン2021. 医学書院, 東京, 2021.
 
21) 竹島多賀夫, 菊井祥二, 山下晋:片頭痛の治療最近の進歩. 神経内科 77:359-367, 2012.
 
22) Ueda K, Ye W, Lombard L, et al:Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan:analysis of data from the Adelphi migraine disease specific programme. J Headache Pain 20:68, 2019.
PubMed
23) Meyers JL, Davis KL, Lenz RA, et al:Treat-ment patterns and characteristics of patients with migraine in Japan:A retrospective analysis of health insurance claims data. Cephalalgia 39:1518-1534, 2019.
 
24) Mulleners WM, Chronicle EP:Anticonvulsants in migraine prophylaxis:a Cochrane review. Cepha-lalgia 28:585-597, 2008.
 
25) Shaygannejad V, Janghorbani M, Ghorbani A, et al:Comparison of the effect of topiramate and sodium valporate in migraine prevention:a ran-domized blinded crossover study. Headache 46:642-648, 2006.
 
26) Hering R, Kuritzky A:Sodium valproate in the prophylactic treatment of migraine:a double-blind study versus placebo. Cephalalgia 12:81-84, 1992.
 
27) Apostol G, Pakalnis A, Laforet GA, et al:Safety and tolerability of divalproex sodium extended-re-lease in the prophylaxis of migraine headaches:results of an open-label extension trial in adoles-cents. Headache 49:36-44, 2009.
 
28) Brandes JL, Saper JR, Diamond M, et al:Topiramate for migraine prevention:a randomized controlled trial. JAMA 291:965-973, 2004.
PubMed
29) Silberstein SD, Lipton RB, Dodick DW, et al:Effi-cacy and safety of topiramate for the treatment of chronic migraine:a randomized, double-blind, placebo-controlled trial. Headache 47:170-180, 2007.
 
30) Mathew NT, Rapoport A, Saper J, et al:Efficacy of gabapentin in migraine prophylaxis. Headache 41:119-128, 2001.
PubMed
31) Watkins AK, Gee M E, Brown JN:Efficacy and safety of levetiracetam for migraine prophylaxis:A systematic review. J Clin Pharm Ther 43:467-475, 2018.
PubMed
32) Ayata C, Jin H, Kudo C, et al:Suppression of cortical spreading depression in migraine prophy-laxis. Ann Neurol 59:652-661, 2006.
 
33) Kurauchi Y, Haruta M, Tanaka R, et al:Propran-olol prevents cerebral blood flow changes and pain-related behaviors in migraine model mice. Biochem Biophys Res Commun 508:445-450, 2019.
 
34) Holroyd KA, Penzien DB, Cordingley GE:Pro-pranolol in the management of recurrent migraine:a meta-analytic review. Headache 31:333-340, 1991.
 
35) 小野垣義男:プロプラノロール(Inderal(R))少量投与による片頭痛の予防. 薬理と治療 8:349-3503, 1980.
 
36) 小沢英輔:片頭痛発作に対するプロプラノロールの予防効果. 薬理と治療 13:248-2493, 1985.
 
37) 寺本純:偏頭痛に対するpropranolol(インデラル(R))の使用経験. 現代医療 21:1001-1005, 1989.
 
38) Jackson JL, Kuriyama A, Kuwatsuka Y, et al:Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 14:e0212785, 2019.
PubMed
39) Tfelt-Hansen P, Standnes B, Kangasneimi P, et al:Timolol vs propranolol vs placebo in common migraine prophylaxis:a double-blind multicenter trial. Acta Neurol Scand 69:1-8, 1984.
PubMed
40) Johannsson V, Nilsson LR, Widelius T, et al:Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache 27:372-374, 1987.
PubMed
41) Ryan RE, Sr:Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J 108(4 Pt 2):1156-1159, 1984.
 
42) van de Ven LL, Franke CL, Koehler PJ:Prophy-lactic treatment of migraine with bisoprolol:a placebo-controlled study. Cephalalgia 17:596-599, 1997.
 
43) Nanda RN, Johnson RH, Gray J, et al:A double blind trial of acebutolol for migraine prophylaxis. Headache 18:20-22, 1978.
 
44) Ekbom K:Alprenolol for migraine prophylaxis. Headache 15:129-132, 1975.
PubMed
45) Ekbom K, Zetterman M:Oxprenolol in the treat-ment of migraine. Acta Neurol Scand 56:181-184, 1977.
 
46) Goldberg MR, Sciberras D, De Smet M, et al:Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist:differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 52:69-76, 2001.
PubMed
47) Tomkins GE, Jackson JL, O'Malley PG, et al:Treatment of chronic headache with antidepres-sants:a meta-analysis. Am J Med 111:54-63, 2001.
 
48) Jackson JL, Shimeall W, Sessums L, et al:Tri-cyclic antidepressants and headaches:systematic review and meta-analysis. BMJ 341:c5222, 2010.
 
49) Strauss LD, Weizenbaum E, Loder EW, et al:Amitriptyline Dose and Treatment Outcomes in Specialty Headache Practice:A Retrospective Cohort Study. Headache 56:1626-1634, 2016.
 
50) Dodick DW, Freitag F, Banks J, et al:Topiramate versus amitriptyline in migraine prevention:a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 31:542-559, 2009.
PubMed
51) Steiner TJ, Ahmed F, Findley LJ, et al:S-fluox-etine in the prophylaxis of migraine:a phase II double-blind randomized placebo-controlled study. Cephalalgia 18:283-286, 1998.
 
52) d'Amato CC, Pizza V, Marmolo T, et al:Fluoxe-tine for migraine prophylaxis:a double-blind trial. Headache 39:716-719, 1999.
 
53) Bank J:A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 34:476-478, 1994.
 
54) Ozyalcin SN, Talu GK, Kiziltan E, et al:The effi-cacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45:144-152, 2005.
 
55) Young WB, Bradley KC, Anjum MW, et al:Duloxetine prophylaxis for episodic migraine in persons without depression:a prospective study. Headache 53:1430-1437, 2013.
PubMed
56) 後藤文男, 田代邦雄, 沓沢尚之, 他:KB-2796(塩酸ロメリジン)の片頭痛に対する臨床評価 後期第II相臨床試験. 臨床評価 23:13-37, 1995.
 
57) 後藤文男, 田代邦雄, 沓沢尚之, 他:片頭痛に対するKB-2796の臨床効果初期第2相臨床試験. 薬理と治療 22:5031-5047, 1994.
 
58) Imai N, Konishi T, Serizawa M, et al:Do the effects of long-term lomerizine administration dif-fer with age? Intern Med 46:683-684, 2007.
 
59) Solomon GD, Steel JG, Spaccavento LJ:Verapamil prophylaxis of migraine. A double-blind, place-bo-controlled study. JAMA 250:2500-2502, 1983.
 
60) Markley HG, Cheronis JC, Piepho RW:Verapamil in prophylactic therapy of migraine. Neurology 34:973-976, 1984.
PubMed
61) Smith R, Schwartz A:Diltiazem prophylaxis in refractory migraine. N Engl J Med 310:1327-1328, 1984.
PubMed
62) Leandri M, Rigardo S, Schizzi R, et al:Migraine treatment with nicardipine. Cephalalgia 10:111-116, 1990.
PubMed
63) Shukla R, Garg RK, Nag D, et al:Nifedipine in migraine and tension headache:a randomised double blind crossover study. J Assoc Physicians India 43:770-772, 1995.
PubMed
64) McArthur JC, Marek K, Pestronk A, et al:Nifedipine in the prophylaxis of classic migraine:a crossover, double-masked, placebo-controlled study of headache frequency and side effects. Neurology 39(2 Pt 1):284-286, 1989.
 
65) Schrader H, Stovner LJ, Helde G, et al:Prophy-lactic treatment of migraine with angiotensin converting enzyme inhibitor(lisinopril):ran-domised, placebo controlled, crossover study. BMJ 322:19-22, 2001.
 
66) Tronvik E, Stovner LJ, Helde G, et al:Prophy-lactic treatment of migraine with an angiotensin II receptor blocker:a randomized controlled trial. JAMA 289:65-69, 2003.
 
67) Diener HC, Gendolla A, Feuersenger A, et al:Telmisartan in migraine prophylaxis:a rand-omized, placebo-controlled trial. Cephalalgia 29:921-927, 2009.
 
68) Gales BJ, Bailey EK, Reed AN, et al:Angioten-sin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann Pharmacother 44:360-366, 2010.
 
69) Dorosch T, Ganzer C A, Lin M, et al:Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventa-tive Treatment of Episodic Migraine in Adults. Curr Pain Headache Rep 23:85, 2019.
 
70) Silberstein SD, Holland S, Freitag F, et al:Evi-dence-based guideline update:pharmacologic treatment for episodic migraine prevention in adults:report of the Quality Standards Subcom-mittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1337-1345, 2012.
 
71) Halker RB, Starling AJ, Vargas BB, et al:ACE and ARB Agents in the Prophylactic Therapy of Migraine-How Effective Are They? Curr Treat Options Neurol 18:15, 2016.
PubMed
72) Benicky J, Sanchez-Lemus E, Honda M, et al:Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36:857-870, 2011.
PubMed
73) Liu H, Kitazato KT, Uno M, et al:Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia:in-vivo and in-vitro studies. J Hypertens 26:1435-1445, 2008.
PubMed
74) Krikov M, Thone-Reineke C, Muller S, et al:Can-desartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens 26:544-552, 2008.
PubMed
75) Diener HC, Dodick DW, Aurora SK, et al:OnabotulinumtoxinA for treatment of chronic migraine:results from the double-blind, ran-domized, placebo-controlled phase of the PREEMPT2 trial. Cephalalgia 30:804-814, 2010.
 
76) Ehrlich M, Hentschke C, Sieder C, et al:Erenumab versus topiramate:post hoc efficacy analysis from the HER-MES study. J Headache Pain 23:141, 2022.
PubMed
77) Stauffer VL, Dodick DW, Zhang Q, et al:Eval-uation of Galcanezumab for the Prevention of Episodic Migraine:The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75:1080-1088, 2018.
 
78) Skljarevski V, Matharu M, Millen BA, et al:Efficacy and safety of galcanezumab for the prevention of episodic migraine:Results of the EVOLVE-2 Phase 3 randomized controlled clini-cal trial. Cephalalgia 38:1442-1454, 2018.
 
79) Detke HC, Millen BA, Zhang Q, et al:Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine:Analysis of the EVOLVE Stud-ies. Headache 60:348-359, 2020.
 
80) Dodick DW, Doty EG, Aurora SK, et al:Medi-cation overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41:340-352, 2021.
 
81) Sakai F, Ozeki A, Skljarevski V:Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine:a phase 2 randomized controlled clinical trial. Cephalalgia Rep 3:1-10, 2020.
 
82) Hirata K, Takeshima T, Sakai F, et al:A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf 20:721-733, 2021.
PubMed
83) Dodick DW, Silberstein SD, Bigal ME, et al:Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine:A Randomized Clinical Trial. JAMA 319:1999-2008, 2018.
 
84) Silberstein SD, Dodick DW, Bigal ME, et al:Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 377:2113-2122, 2017.
PubMed
85) Silberstein SD, Cohen JM, Seminerio MJ, et al:The impact of fremanezumab on medication over-use in patients with chronic migraine:subgroup analysis of the HALO CM study. J Headache Pain 21:114, 2020.
PubMed
86) Sakai F, Suzuki N, Kim BK, et al:Efficacy and safety of fremanezumab for chronic migraine pre-vention:Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61:1092-1101, 2021.
 
87) Sakai F, Suzuki N, Kim BK, et al:Efficacy and safety of fremanezumab for episodic migraine prevention:Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61:1102-1111, 2021.
PubMed
88) Goadsby PJ, Reuter U, Hallstrom Y, et al:A Con-trolled Trial of Erenumab for Episodic Migraine. N Engl J Med 377:2123-2132, 2017.
 
89) Dodick DW, Ashina M, Brandes JL, et al:ARISE:A Phase 3 randomized trial of erenumab for epi-sodic migraine. Cephalalgia 38:1026-1037, 2018.
 
90) Sakai F, Takeshima T, Tatsuoka Y, et al:A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Headache 59:1731-1742, 2019.
PubMed
91) Takeshima T, Sakai F, Hirata K, et al:Erenumab treatment for migraine prevention in Japanese patients:Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61:927-935, 2021.
PubMed
92) Tepper SJ, Diener HC, Ashina M, et al:Erenumab in chronic migraine with medication overuse:Subgroup analysis of a randomized trial. Neurology 92:e2309-e2320, 2019.
PubMed
93) Ashina M, Saper J, Cady R, et al:Eptinezumab in episodic migraine:A randomized, double-blind, placebo-controlled study(PROMISE-1). Cepha-lalgia 40:241-254, 2020.
 
94) Lipton RB, Goadsby PJ, Smith J, et al:Effi-cacy and safety of eptinezumab in patients with chronic migraine:PROMISE-2. Neurology 94:e1365-e1377, 2020
 
95) Diener HC, Marmura MJ, Tepper SJ, et al:Effi-cacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache:Subgroup anal-ysis of PROMISE-2. Headache 61:125-136, 2021.
 
96) Dodick DW, Gottschalk C, Cady R, et al:Eptin-ezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 60:2220-2231, 2020.
 
97) Winner PK, McAllister P, Chakhava G, et al:Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack:A Rand-omized Clinical Trial. JAMA 325:2348-2356, 2021.
 
98) Artama M, Auvinen A, Raudaskoski T, et al:Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurol-ogy 64:1874-1878, 2005.
 
99) Morrow J, Russell A, Guthrie E, et al:Malfor-mation risks of antiepileptic drugs in pregnancy:a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychia-try 77:193-198, 2006.
 
100) Vajda FJ, Hitchcock A, Graham J, et al:Foetal malformations and seizure control:52 months data of the Australian Pregnancy Registry. Eur J Neurol 13:645-654, 2006.
PubMed
101) Meador KJ, Baker GA, Browning N, et al:Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years(NEAD study):a pro-spective observational study. Lancet Neurol 12:244-252, 2013.
 
102) Christensen J, Gronborg TK, Sorensen MJ, et al:Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 309:1696-1703, 2013.
 
103) CG Briggs:Drugs in Pregnancy and Lactation. A Reference Guide to Fetal Neonatal Risk 11th edition, Lippincott Williams and Wilkins, Phila-delphia 2017.
 
104) MacGregor EA:Migraine in pregnancy and lactation:a clinical review. J Fam Plann Reprod Health Care 33:83-93, 2007.
PubMed
105) Pringsheim T, Davenport W, Mackie G, et al:Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39(2 Suppl 2):S1-59, 2012.
 
106) American Headache Society:The American Headache Society Position Statement On Inte-grating New Migraine Treatments Into Clinical Practice. Headache 59:1-18, 2019.
 
107) Sacco S, Bendtsen L, Ashina M, et al:European headache federation guideline on the use of mon-oclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine pre-vention. J Headache Pain 20:6, 2019.
 
108) Sacco S, Amin FM, Ashina M, et al:European Headache Federation guideline on the use of mon-oclonal antibodies targeting the calcitonin gene related peptide pathway for migraine preven-tion-2022 update. J Headache Pain 23:67, 2022.
 
109) Blau JN:Migraine:theories of pathogenesis. Lancet 339:1202-1207, 1992.
PubMed
110) 厚生労働省:最適使用推進ガイドライン ガルガネズマブ(遺伝子組換え). https://www.mhlw.go.jp/content/12404000/000768564.pdf
 
111) 厚生労働省:最適使用推進ガイドライン フレマネズマブ(遺伝子組換え). https://www.pmda.go.jp/files/000248994.pdf
 
112) 厚生労働省:最適使用推進ガイドライン エレヌマブ(遺伝子組換え). https://www.pmda.go.jp/files/000248990.pdf
 
P.152 掲載の参考文献
1) Ashina M, Goadsby PJ, Reuter U, et al:Long-term efficacy and safety of erenumab in migraine prevention:Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716-1725, 2021.
PubMed
2) Barbanti P, Aurilia C, Egeo G, et al:Late Response to Anti-CGRP Monoclonal Antibodies in Migraine:A Multicenter Prospective Observa-tional Study. Neurology 101:482-488, 2023.
 
3) Ziegeler C, May A:Non-Responders to Treat-ment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class. Headache 60:469-470, 2020.
 
4) Porta-Etessam J, Gonzalez-Garcia N, Guer-rero AL, et al:Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class. Neurologia(Engl Ed) 36:638-640, 2021.
 
5) Patier Ruiz I, Sanchez-Rubio Ferrandez J, et al:Early Experiences in Switching between Mono-clonal Antibodies in Patients with Nonresponsive Migraine in Spain:A Case Series. Eur Neurol 85:132-135, 2022.
 
6) Overeem LH, Lange KS, Fitzek MP, et al:Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine:A real-world cohort study. Front Neurol 14:1154420, 2023.
 
7) Overeem LH, Peikert A, Hofacker MD, et al:Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine:A multi-center retrospective cohort study. Cephalalgia 42:291-301, 2022.
 
8) Iannone LF, Burgalassi A, Vigani G, et al:Switching anti-CGRP(R) monoclonal antibod-ies in multi-assessed non-responder patients and implications for ineffectiveness criteria:A retrospective cohort study. Cephalalgia 43:3331024231160519, 2023.
 
9) Kaltseis K, Filippi V, Frank F, et al:Monoclonal antibodies against CGRP(R):non-responders and switchers:real world data from an austrian case series. BMC Neurol 23:174, 2023.
PubMed
10) Straube A, Broessner G, Gaul C, et al:Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway:a subgroup analysis of the Finesse Study. J Headache Pain 24:59, 2023
PubMed
11) Ihara K, Ohtani S, Watanabe N, et al:Switch-ing between anti-calcitonin gene-related peptide monoclonal antibodies:A comparison of monthly and quarterly dosing. J Neurol Sci 453:120811, 2023.
 
12) American Headache Society:The American Headache Society Position Statement On Inte-grating New Migraine Treatments Into Clinical Practice. Headache 59:1-18, 2019.
 
13) GoodRx:http://www.goodrx.com
 
14) Sacco S, Amin FM, Ashina M, et al:European Headache Federation guideline on the use of mon-oclonal antibodies targeting the calcitonin gene related peptide pathway for migraine preven-tion-2022 update. J Headache Pain 23:67, 2022.
 
15) Pascual J, Nunez M, Panni T, et al:Burden and Unmet Needs in Migraine Patients:Results from the OVERCOME(Spain) Study. Pain Ther 12:1209-1220, 2023.
PubMed
16) National Health Insurance Administration, Min-istry of Health and Welfare:National Health Insurance in Taiwan.
 
17) Wang SJ, Fuh JL, Young YH, et al:Prevalence of migraine in Taipei, Taiwan:a population-based survey. Cephalalgia 20:566-572, 2000.
PubMed
18) Safiri S, Pourfathi H, Eagan A, et al:Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293-e309, 2022.
PubMed
19) Song TJ, Cho SJ, Kim WJ, et al:Sex Differences in Prevalence, Symptoms, Impact, and Psychi-atric Comorbidities in Migraine and Probable Migraine:A Population-Based Study. Headache 59:215-223, 2019.
 
20) Lance JW, Anthony M:Some clinical aspects of migraine. A prospective survey of 500 patents. Arch Neurol 15:356-361, 1966.
 
21) Kronenfeld LW, Reba-Harrelson L, Von Holle A, et al:Ethnic and racial differences in body size perception and satisfaction. Body Image 7:131-136, 2010.
PubMed
22) Takizawa T, Ohtani S, Watanabe N, et al:Real-world evidence of galcanezumab for migraine treatment in Japan:a retrospective analysis. BMC Neurol 22:512, 2022.
PubMed
23) Ihara K, Ohtani S, Watanabe N, et al:Predict-ing response to CGRP-monoclonal antibodies in patients with migraine in Japan:a single-centre retrospective observational study. J Headache Pain 24:23, 2023.
 
24) Ito Y, Mitsufuji T, Okada M, et al:Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse:A Single-center Retrospective Study. Intern Med, 2023. [Epub ahead of print]
 
25) Suzuki K, Suzuki S, Shiina T, et al:Effectiveness of three calcitonin gene-related peptide mon-oclonal antibodies for migraine:A 12-month, single-center, observational real-world study in Japan. Cephalalgia 43:3331024231177649, 2023.
 
26) Suzuki S, Suzuki K, Shiina T, et al:Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol 14:1220285, 2023.
PubMed
27) Suzuki K, Suzuki S, Shiina T, et al:Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study. J Neurol 270:4377-4384, 2023.
PubMed
28) 滝沢翼, 井原慶子:頭痛研究の現状と展望. 脳神経内科 98:318-324, 2023.
 
29) Barbanti P, Aurilia C, Egeo G, et al:Erenumab in the prevention of high-frequency episodic and chronic migraine:Erenumab in Real Life in Italy(EARLY), the first Italian multicenter, prospec-tive real-life study. Headache 61:363-372, 2021.
 
30) Frattale I, Caponnetto V, Casalena A, et al:Asso-ciation between response to triptans and response to erenumab:real-life data. J Headache Pain 22:1, 2021.
 
31) Silvestro M, Tessitore A, Scotto di Clemente F, et al:Refractory migraine profile in CGRP-monoclo-nal antibodies scenario. Acta Neurol Scand 144:325-333, 2021.
 
32) Zecca C, Cargnin S, Schankin C, et al:Clinic and genetic predictors in response to erenumab. Eur J Neurol 29:1209-1217, 2022.
PubMed
33) Pensato U, Baraldi C, Favoni V, et al:Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neu-rol Sci 43:1273-1280, 2022.
 
34) Baraldi C, Castro FL, Cainazzo MM, et al:Predic-tors of response to erenumab after 12 months of treatment. Brain Behav 11:e2260, 2021.
 
35) Bottiroli S, De Icco R, Vaghi G, et al:Psychologi-cal predictors of negative treatment outcome with Erenumab in chronic migraine:data from an open label long-term prospective study. J Head-ache Pain 22:114, 2021.
 
36) Vernieri F, Altamura C, Brunelli N, et al:Rapid response to galcanezumab and predictive factors in chronic migraine patients:A 3-month obser-vational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29:1198-1208, 2022.
 
37) Iannone LF, Fattori D, Benemei S, et al:Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs 36:191-202, 2022.
PubMed
38) Barbanti P, Egeo G, Aurilia C, et al:Freman-ezumab in the prevention of high-frequency episodic and chronic migraine:a 12-week, mul-ticenter, real-life, cohort study(the FRIEND study). J Headache Pain 23:46, 2022.
 
39) Lowe M, Murray L, Tyagi A, et al:Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine:a clinical service evaluation. J Headache Pain 23:86, 2022.
 
40) Kim SA, Jang H, Lee MJ:Predictors of galcane-zumab response in a real-world study of Korean patients with migraine. Sci Rep 13:14825, 2023.
 
41) Lee HC, Cho S, Kim BK:Predictors of response to galcanezumab in patients with chronic migraine:a real-world prospective observational study. Neurol Sci 44:2455-2463, 2023.
 
42) Barbanti P, Egeo G, Aurilia C, et al:Predictors of response to anti-CGRP monoclonal antibodies:a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138, 2022.
PubMed
43) Argyriou AA, Dermitzakis EV, Xiromerisiou G, et al:Predictors of Response to Fremanezumab in Migraine Patients with at Least Three Previous Preventive Failures:Post Hoc Analysis of a Pro-spective, Multicenter, Real-World Greek Registry. J Clin Med 12:3218, 2023.
 
44) Hong JB, Lange KS, Overeem LH, et al:A Scop-ing Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies:Predicting Response. Pharmaceuticals(Basel)16:934, 2023.
 
P.159 掲載の参考文献
1) Goadsby PJ, Dodick DW, Leone M, et al:Trial of Galcanezumab in Prevention of Episodic Cluster Headache. N Engl J Med 381:132-141, 2019.
PubMed
2) Dodick DW, Goadsby PJ, Lucas C, et al:Phase 3 randomized, placebo-controlled study of galcane-zumab in patients with chronic cluster headache:Results from 3-month double-blind treatment. Cephalalgia Int J Headache 40:935-948, 2020.
 
3) Riesenberg R, Gaul C, Stroud CE, et al:Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. Cephalalgia Int J Headache 42:1225-1235, 2022.
PubMed
4) Kielbasa W, Helton DL:A new era for migraine:Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcan-ezumab, an anti-CGRP antibody. Cephalalgia Int J Headache 39:1284-1297, 2019.
 
5) Ashina M, Saper J, Cady R, et al:Eptinezumab in episodic migraine:A randomized, double-blind, placebo-controlled study(PROMISE-1). Cepha-lalgia Int J Headache 40:241-254, 2020.
 
6) Lipton RB, Goadsby PJ, Smith J, et al:Effi-cacy and safety of eptinezumab in patients with chronic migraine:PROMISE-2. Neurology 94:e1365-e1377, 2020.
 
7) Chiang CC, Schwedt TJ:Calcitonin gene-related peptide(CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclo-nal antibodies and gepants. Prog Brain Res 255:143-170, 2020.
 
8) Lipton RB, Dodick DW, Ailani J, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine:The ACHIEVE II Ran-domized Clinical Trial. JAMA 322:1887-1898, 2019.
 
9) Jakate A, Blumenfeld AM, Boinpally R, et al:Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine:A ran-domized phase 1b drug-drug interaction study. Headache 61:642-652, 2021.
 
10) Croop R, Goadsby PJ, Stock DA, et al:Efficacy, safety, and tolerability of rimegepant orally dis-integrating tablet for the acute treatment of migraine:a randomised, phase 3, double-blind, placebo-controlled trial. Lancet Lond Engl 394:737-745, 2019.
 
11) Croop R, Lipton RB, Kudrow D, et al:Oral rimegepant for preventive treatment of migraine:a phase 2/3, randomised, double-blind, place-bo-controlled trial. Lancet Lond Engl 397:51-60, 2021.
 
12) Ailani J, Lipton RB, Goadsby PJ, et al:Atogepant for the Preventive Treatment of Migraine. N Engl J Med 385:695-706, 2021.
PubMed
13) Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine:A Phase 2/3 double-blind, randomized, placebo-con-trolled, dose-ranging trial. Headache 62:1153-1163, 2022.
 
P.164 掲載の参考文献
1) Steiner TJ, Stovner LJ, Vos T, et al:Migraine is first cause of disability in under 50s:will health politicians now take notice? J Headache Pain 19:17, 2018.
 
2) Sakai F, Igarashi H:Prevalence of migraine in Japan:a nationwide survey. Cephalalgia 17:15-22, 1997.
PubMed
3) Hepp Z, Dodick DW, Varon SF, et al:Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478-488, 2015.
PubMed
4) Overeem LH, Peikert A, Hofacker MD, et al:Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine:A multi-center retrospective cohort study. Cepha-lalgia 42:291-301, 2022.
 
5) Deen M, Correnti E, Kamm K, et al;European Headache Federation School of Advanced Studies(EHF-SAS):Blocking CGRP in migraine patients a review of pros and cons. J Headache Pain 18:96, 2017.
 
6) 鮎澤聡, 松村明:ニューロモデュレーションの現状と展望. 脳神経外科ジャーナル 26:864-872, 2017.
 
7) 竹島多賀夫, 菊井祥二, 團野大介:デバイスを用いた難治性頭痛の治療. 神経内科 86:723-730, 2017.
 
8) 團野大介, 飯ケ谷美峰, 今井昇, 他:眼窩上経皮的末梢神経電気刺激装置(Cefaly(R))を用いた高頻度片頭痛および慢性片頭痛に対する安全性, および忍容性, 予防効果についての他施設共同前向き研究. 日本頭痛学会誌 45:70-74, 2018.
 
9) Reuter U, McClure C, Liebler E, et al:Non-in-vasive neuromodulation for migraine and cluster headache:a systematic review of clinical trials. J Neurol Neurosurg Psychiatry 90:796-804, 2019.
 
10) Tassorelli C, Grazzi L, de Tommaso M, et al:PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine:The randomized PRESTO study. Neurology 91:e364-e373, 2018.
 
11) Silberstein SD, Calhoun AH, Lipton RB, et al:Chronic migraine headache prevention with non-invasive vagus nerve stimulation:The EVENT study. Neurology 87:529-538, 2016.
 
12) Diener HC, Goadsby PJ, Ashina M, et al:Non-in-vasive vagus nerve stimulation(nVNS)for the preventive treatment of episodic migraine:The multicentre, double-blind, randomised, sham-con-trolled PREMIUM trial. Cephalalgia 39:1475-1487, 2019.
 
13) Oshinsky ML, Murphy AL, Hekierski H Jr, et al:Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain 155:1037-1042, 2014.
PubMed
14) Chou DE, Shnayderman Yugrakh M, Winegarner D, et al:Acute migraine therapy with external trigeminal neurostimulation(ACME):A ran-domized controlled trial. Cephalalgia 39:3-14, 2019.
 
15) Schoenen J, Vandersmissen B, Jeangette S, et al:Migraine prevention with a supraorbital transcu-taneous stimulator:a randomized controlled trial. Neurology 80:697-704, 2013.
 
16) Danno D, Iigaya M, Imai N, et al:The safety and preventive effects of a supraorbital transcutaneous stimulator in Japanese migraine patients. Sci Rep 9:9900, 2019.
PubMed
17) Magis D, D'Ostilio K, Thibaut A, et al:Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia 37:881-891, 2017.
PubMed
18) Magis D, Sava S, d'Elia TS, et al:Safety and patients'satisfaction of transcutaneous supraor-bital neurostimulation(tSNS)with the Cefaly(R)device in headache treatment:a survey of 2,313 headache sufferers in the general population. J Headache Pain 14:95, 2013.
 
19) Lipton RB, Dodick DW, Silberstein SD, et al:Single-pulse transcranial magnetic stimula-tion for acute treatment of migraine with aura:a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol 9:373-380, 2010.
 
20) Starling AJ, Tepper SJ, Marmura MJ, et al:A multicenter, prospective, single arm, open label, observational study of sTMS for migraine pre-vention(ESPOUSE Study). Cephalalgia 38:1038-1048, 2018.
 
21) Andreou AP, Holland PR, Akerman S, et al:Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain 139:2002-2014, 2016.
PubMed
22) Tepper SJ, Grosberg B, Daniel O, et al:Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized con-trolled trial. Headache 62:989-1001, 2022.
 
23) 日本神経学会, 日本頭痛学会, 日本神経治療学会(監), 「頭痛の診療ガイドライン」作成委員会(編):頭痛の診療ガイドライン2021, 医学書院, 東京, 2021.
 

【研究】

P.174 掲載の参考文献
1) 橋本悦子, 谷合麻紀子:NAFLD/NASHの疾患概念の変遷問われるNASH診断の意義. 肝臓 59(2):83-91, 2018.
 
2) 稲垣豊:今月のテーマ(総論):肝線維化をめぐる最新情報肝線維化研究の進歩と臨床展開. 日本消化器病学会雑誌 117:9-19, 2020.
 
3) Yanguas SC, Cogliati B, Willebrords J, et al:Experimental models of liver fibrosis. Arch Toxi-col 90(5):1025-1048, 2016.
 
4) Owada Y, Tamura T, Tanoi T, et al:Novel non-alcohlic steatohepatitis model with histopatho-logical and insulin-resistant features. Pathology International 68:12-22, 2018.
 
5) 川崎由紀子, 大津尚子, 今泉隆人, 他:四塩化炭素および肝臓X受容体アゴニストの投与による非アルコール性脂肪性肝炎モデルに対するBezafi-brateの作用. 医学と薬学 78(2):149-157, 2021.
 
6) オゾン層の保護のためのウイーン条約. 昭和63年12月27日号外条約第8号.
 
7) 発がんのおそれのある有機溶剤の今後の対応. No. 71厚生労働省化学物質のリスク評価検討会, 2013年7月.
 
8) Wallace MC, Hamesch K, Lunova M, et al:Stand-ard operating procedures in experimental liver research:thioacetamide model in mice and rats. Lab Anim 49(1 Suppl):21-29, 2015.
 
9) Chang GR, Lin WL, Lin TC, et al:The Amelio-rative Effects of Saikosaponin in Thioacetamide-Induced Liver Injury and Non-Alcoholic Fatty Liver Disease in Mice. Int J Mol Sci 22(21):11383, 2021.
 
10) Yimin, Furumaki H, Matsuoka S, et al:A novel murine model for non-alcoholic steatohepatitis developed by combination of a high-fat diet and oxidized low-density lipoprotein. Lab Invest 92(2):265-281, 2012.
PubMed
11) 鎌田佳宏, 三善英知, 竹原徹郎:今月のテーマ:NAFLDの診療・研究のupdate NAFLDの診断と検査法のupdate. 日本消化器病学会雑誌 111:25-34, 2014.
 
12) Kishioka T, Iida C, Fujii K, et al:Effect of dime-thyl sulphoxide on oxidative stress, activation of mitogen activated protein kinase and necrosis caused by thioacetamide in the rat liver. Eur J Pharmacol 564(1-3):190-195, 2007.
 
13) 菊池淳, 小山研二, 大和田康夫, 他:Thioaceta-mideによる実験的肝硬変の機能と形態に関する研究. 肝臓 28(1):53-61, 1987.
 
14) Younes M, Albrecht M, Siegers CP:Interre-lationship between in vivo lipid peroxidation, microsomal Ca2+ -sequestration activity and hepatotoxicity in rats treated with carbon tetra-chloride, cumene hydroperoxide or thioacetamide. Res Commun Chem Pathol Pharmacol 40(3):405-415, 1983.
PubMed

【Diagnosis】

P.180 掲載の参考文献
1) Hooks MA:Tacrolimus, a New Immunosup-pressant-A Review of the Literature. Annals of Pharmacotherapy 28(4):501-511, 1994.
 
2) Schreiber SL, Crabtree GR:The mechanism of action of cyclosporin A and FK506. Immunol Today 13(4):136-142, 1992.
PubMed
3) Wong SH:Therapeutic drug monitoring for immu-nosuppressants. Clin Chim Acta 313(1-2):241-253, 2001.
 
4) 市原清志, 細萱茂実, 奥谷竜太, 他:定量分析法における検出限界および定量限界の評価法. 臨床化学 35(3):280-294, 2006.
 
P.191 掲載の参考文献
1) 日本小児呼吸器学会・日本小児感染症学会:小児呼吸器感染症診療ガイドライン2022, 石和田稔彦, 新庄正宜(監), 協和企画, 東京, 2022.
 
2) 光野典子, 播智宏, 玉川信吉, 他:A群レンサ球菌迅速診断キットの基礎的検討. 感染症学雑誌 80:665-673, 2006.
 
3) Kohdera U, Kino M, Ito M:Detection of adenovirus DNA in throat swabs and blood by SYBR green real-time PCR assay in patients with adenovirus-associated tonsillitis. Japanese journal of infectious diseases 59(6):394-396, 2006.
PubMed
4) 国際的に脅威となる感染症対策の強化のための国際連携等関係閣僚会議:薬剤耐性(AMR)対策アクションプラン 2016-2020, 2016.
 
5) 国際的に脅威となる感染症対策の強化のための国際連携等関係閣僚会議:薬剤耐性(AMR)対策アクションプラン 2023-2027, 2023.
 
6) 厚生労働省健康局結核感染症課:抗微生物薬適正使用の手引き第二版, 2019.
 

書評

最近チェックした商品履歴

Loading...